Pheochromocytoma: The expanding genetic differential diagnosis.
The DOI matches its Crossref record; 103 of the 103 references it cites were found in a registry or an index.
Abstract
Pheochromocytomas and paragangliomas are tumors of the autonomic nervous system; pheochromocytomas are tumors of the adrenal medulla, and paragangliomas are extra-adrenal tumors arising from either the sympathetic nervous system or parasympathetic ganglia. It has previously been estimated that approximately 10%-15% of pheochromocytomas are due to hereditary causes. However, our increased understanding of the three hereditary syndromes (neurofibromatosis 1, multiple endocrine neoplasia type 2, and von Hippel-Lindau syndrome) in which pheochromocytoma is found and the recent discovery that mutations in genes in the succinate dehydrogenase family (SDHB and SDHD) predispose to pheochromocytoma have necessitated a re-evaluation of the genetic basis of pheochromocytoma. These studies indicate that the frequency of germline mutations associated with isolated pheochromocytoma is higher than previously estimated, with both hospital-based series and a large population-based series indicating that the frequency of germline mutations in RET, VHL, SDHB, and SDHD taken together approximates 20%. In all patients with pheochromocytoma, including those with known hereditary syndrome or a positive family history, the frequency of germline mutations in these four genes together approaches 30%. Given the frequency of germline mutations, consideration should be given to genetic counseling for all patients with pheochromocytoma and is particularly important for individuals with a positive family history, multifocal disease, or a diagnosis before age 50. Identification of patients with hereditary pheochromocytoma is important because it can guide medical management in mutation-positive patients and their families. This review provides an overview of the known genetic syndromes that are commonly associated with pheochromocytoma, examines recent data on the association of germline mutations in the succinate dehydrogenase gene family with pheochromocytoma, and suggests guidelines for the genetic evaluation of pheochromocytoma patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pheochromocytomas can arise as a result of mutations in the following disease-associated genes: RET in multiple endocrine neoplasia type 2 (MEN2); VHL in von Hippel-Lindau disease (VHL); NF1 in neurofibromatosis type 1 (NF1); and succinate dehydrogenase (SDH) subunits B, C, or D in familial paraganglioma syndromes type 4 (PGL4), type 3 (PGL3), and type 1 (PGL1), respectively [2].”
From A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas (2005) · cites this paper as [2]
Citations
Cites
The American Journal of Human Genetics
S., J. (1950) · Population (French Edition) · doi:10.2307/1523704 · Cited by 5,028
(2015) · American Journal Of Pathology · doi:10.2353/ajpath · Cited by 4,908
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
CONSENSUS: Guidelines for Diagnosis and Therapy of MEN Type 1 and Type 2
Brandi, M. L. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.12.5658 · Cited by 2,031
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966 · cited 1×
“Germline mutations in the RET proto-oncogene, which encodes a transmembrane receptor tyrosine kinase and is expressed in cells derived from the neural crest, are responsible for MEN 2 ( 34 ).”
BackgroundMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
Type 1 Neurofibromatosis Gene: Identification of a Large Transcript Disrupted in Three NF1 Patients
Wallace, M. R., Marchuk, D. A., Andersen, L. B., Letcher, R., Odeh, H. M., Saulino, A. M., Fountain, J. W., Brereton, A., Nicholson, J., Mitchell, A. L., et al. (1990) · Science · doi:10.1126/science.2134734 · Cited by 1,475
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Gutmann, D. H. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550010065042 · Cited by 1,359
Horder, & Harnett, W. L. (1941) · BMJ · doi:10.1136/bmj.1.4186.493 · Cited by 1,314
Biochemical Diagnosis of Pheochromocytoma: Which Test Is Best?
Lenders, J. W. M., Pacak, K., Walther, M. M., Linehan, W. M., Mannelli, M., Friberg, P., Keiser, H. R., Goldstein, D. S., & Eisenhofer, G. (2002) · JAMA · doi:10.1001/jama.287.11.1427 · Cited by 1,134
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Neurofibromatosis, Phenotype, Natural History, and Pathogenesis
Riccardi, V. M., & Smirniotopoulos, J. (1992) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199211000-00009 · Cited by 893
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Mutations in SDHC cause autosomal dominant paraganglioma, type 3
Niemann, S., & Müller, U. (2000) · Nature Genetics · doi:10.1038/81551 · Cited by 875
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
Activation of RET as a Dominant Transforming Gene by Germline Mutations of MEN2A and MEN2B
Santoro, M., Carlomagno, F., Romano, A., Bottaro, D. P., Dathan, N. A., Grieco, M., Fusco, A., Vecchio, G., Matoskova, B., Kraus, M. H., et al. (1995) · Science · doi:10.1126/science.7824936 · Cited by 841
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G., Elledge, S. J., Conaway, R. C., et al. (1999) · Science · doi:10.1126/science.284.5414.657 · Cited by 781
Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma
Pacak, K., Linehan, W. M., Eisenhofer, G., Walther, M. M., & Goldstein, D. S. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-4-200102200-00016 · Cited by 618 · cited 2×
“Several genetic syndromes, all of which are transmitted in an autosomal dominant fashion, are known to be associated with an increased risk for pheochromocytoma, including von Hippel–Lindau (VHL) syndrome, multiple endocrine neoplasia type 2 (MEN 2), which is associated with mutations in the RET proto-oncogene, and ne…”
BackgroundInfluentialVon Hippel-Lindau disease: a genetic study.
Maher, E. R., Iselius, L., Yates, J. R., Littler, M., Benjamin, C., Harris, R., Sampson, J., Williams, A., Ferguson-Smith, M. A., & Morton, N. (1991) · Journal of Medical Genetics · doi:10.1136/jmg.28.7.443 · Cited by 595
Epidemiology of neurofibromatosis type 1
Friedman, J. M. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990326)89:1<1::aid-ajmg3>3.0.co;2-8 · Cited by 577
Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
Duan, D. R., Pause, A., Burgess, W. H., Aso, T., Chen, D. Y. T., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., & Klausner, R. D. (1995) · Science · doi:10.1126/science.7660122 · Cited by 568
PROSPECTIVE RANDOMISED TRIAL OF EARLY DIETARY PROTEIN RESTRICTION IN CHRONIC RENAL FAILURE
Rosman, J., Ter Wee, P., Meijer Truus, S., Piers-Becht, P. M., Sluiter, W., & Donker, A. M. (1984) · The Lancet · doi:10.1016/s0140-6736(84)90818-3 · Cited by 555
Huson, S. M., Compston, D. A., Clark, P., & Harper, P. S. (1989) · Journal of Medical Genetics · doi:10.1136/jmg.26.11.704 · Cited by 540
Eng, C., SmIth, D. P., MullIgan, L. M., Nagal, M. A., Healey, C. S., Ponder, M. A., Gardner, E., Scheumann, G. F. W., Jackson, C. E., Tunnacllffe, A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.2.237 · Cited by 537
(1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.5.1730 · Cited by 484
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
Stolle, C., Glenn, G., Zbar, B., Humphrey, J. S., Choyke, P., Walther, M., Pack, S., Hurley, K., Andrey, C., Klausner, R., et al. (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)12:6<417::aid-humu8>3.0.co;2-k · Cited by 479
Ohh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., & Iliopoulos, O. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80096-9 · Cited by 477
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene
Stolle, C. A., Glenn, G. M., Zbar, B., Humphrey, J. S., Choyke, P. L., Walther, M. M., Pack, S., Hurley, K., Andrey, C., Klausner, R. D., et al. (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)12:6<431::aid-humu10>3.0.co;2-y · Cited by 477
Pheochromocytomas, Multiple Endocrine Neoplasia Type 2, and von Hippel-Lindau Disease
Neumann, H., Berger, D. P., Sigmund, G., Blum, U., Schmidt, D., Parmer, R. J., Volk, B., & Kirste, G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292103 · Cited by 465
Clinical Experience Over 48 Years With Pheochromocytoma
Goldstein, R. E., O’Neill, J. A., Holcomb, G. W., Morgan, W. M., Neblett, W. W., Oates, J. A., Brown, N., Nadeau, J., Smith, B., Page, D. L., et al. (1999) · Annals of Surgery · doi:10.1097/00000658-199906000-00001 · Cited by 464
Zöller, M. E. T., Rembeck, B., Odén, A., Samuelsson, M., & Angervall, L. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970601)79:11<2125::aid-cncr9>3.3.co;2-b · Cited by 395
Hoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382
Molecular genetics of neurofibromatosis type 1 (NF1).
Shen, M. H., Harper, P. S., & Upadhyaya, M. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.1.2 · Cited by 377
Clifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
VON RECKLINGHAUSEN′S DISEASE AND PHEOCHROMOCYTOMAS
Walther, M. M., Herring, J., Enquist, E., Keiser, H. R., & Linehan, W. M. (1999) · Journal of Urology · doi:10.1016/s0022-5347(05)68171-2 · Cited by 361
Baysal, B. E., Willett-Brozick, J. E., Lawrence, E. C., Drovdlic, C. M., Savul, S. A., McLeod, D. R., Yee, H. A., Brackmann, D. E., Slattery, W. H., Myers, E. N., et al. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.3.178 · Cited by 339
GENOMIC IMPRINTING IN HEREDITARY GLOMUS TUMOURS: EVIDENCE FOR NEW GENETIC THEORY
Van Der Mey, A. L., Maaswinkel-Mooy, P., Cornelisse, C., Schmidt, P., & Van De Kamp, J. P. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91908-9 · Cited by 305
Ruttledge, M. H., Andermann, A. A. J., Phelan, C. M., Claudio, J. O., Han, F., Chrétien, N., Rangaratnam, S., MacCollin, M., Short, P., Parry, D. M., et al. (1996) · PubMed · Cited by 293
Gimm, O., Armanios, M. Y., Dziema, H., Neumann, H. P. H., & Eng, C. (2000) · PubMed · Cited by 274
Mulligan, L. M., MARSH, D. J., ROBINSON, B. G., SCHUFFENECKER, I., ZEDENIUS, J., LIPS, C. J. M., GAGEL, R. F., TAKAI, S. ‐., NOLL, W. W., FINK, M., et al. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01208.x · Cited by 272
Eisenhofer, G., Walther, M. M., Huynh, T.-T., Li, S.-T., Bornstein, S. R., Vortmeyer, A., Mannelli, M., Goldstein, D. S., Linehan, W. M., Lenders, J. W. M., et al. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.5.7496 · Cited by 267
A genetic register for von Hippel-Lindau disease.
Maddock, I. R., Moran, A., Maher, E. R., Teare, M. D., Norman, A., Payne, S. J., Whitehouse, R., Dodd, C., Lavin, M., Hartley, N., et al. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.2.120 · Cited by 263
de Leon, M. P. (1994) · Recent Results in Cancer Research · doi:10.1007/978-3-642-85076-9_7 · Cited by 260
WALTHER, M. M., REITER, R., KEISER, H. R., CHOYKE, P. L., VENZON, D., HURLEY, K., GNARRA, J. R., REYNOLDS, J. C., GLENN, G. M., ZBAR, B., et al. (1999) · Journal of Urology · doi:10.1097/00005392-199909010-00004 · Cited by 255
Germline SDHD mutation in familial phaeochromocytoma
Astuti, D., Douglas, F., Lennard, T. W., Aligianis, I. A., Woodward, E. R., Evans, D. G. R., Eng, C., Latif, F., & Maher, E. R. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04378-6 · Cited by 246
Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis
Hansford, J. R., & Mulligan, L. M. (2000) · Journal of Medical Genetics · doi:10.1136/jmg.37.11.817 · Cited by 241
Familial carotid body tumors: Case report and epidemiologic review
Grufferman, S., Gillman, M. W., Pasternak, L. R., Peterson, C. L., & Young, W. G. (1980) · Cancer · doi:10.1002/1097-0142(19801101)46:9<2116::aid-cncr2820460934>3.0.co;2-s · Cited by 240
Hereditary paraganglioma targets diverse paraganglia: Table 1
Baysal, B. E. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.9.617 · Cited by 235
Pheochromocytoma: New concepts and future trends
Bravo, E. L. (1991) · Kidney International · doi:10.1038/ki.1991.244 · Cited by 222
Management of Pheochromocytomas in Patients with Multiple Endocrine Neoplasia Type 2 Syndromes
Lairmore, T. C., Ball, D. W., Baylin, S. B., & Wells, S. A. (1993) · Annals of Surgery · doi:10.1097/00000658-199306000-00001 · Cited by 218
Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors.
Prowse, A. H., Webster, A. R., Richards, F. M., Richard, S., Olschwang, S., Resche, F., Affara, N. A., & Maher, E. R. (1997) · Europe PMC (PubMed Central) · Cited by 215
Lubensky, I. A., Gnarra, J. R., Bertheau, P., Walther, M. M., Linehan, W. M., & Zhuang, Z. (1996) · PubMed Central · Cited by 187
Distribution of 13 truncating mutations in the neurofibromatosis 1 gene
Heim, R. A., Kam-Morgan, L. N. W., Binnie, C. G., Corns, D. D., Cayouette, M. C., Farber, R. A., Aylsworth, A. S., Silverman, L. M., & Luce, M. C. (1995) · Human Molecular Genetics · doi:10.1093/hmg/4.6.975 · Cited by 185 · cited 1×
“When NF1 patients are examined at autopsy, the prevalence of pheochromocytoma is slightly higher (3.3%–13.0%) ( 24 ).”
BackgroundInfluentialEng, C., Mulligan, L. M., Smith, D. P., Healey, C. S., Frilling, A., Raue, F., Neumann, H. P. H., Ponder, M. A., & Ponder, B. A. J. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb01903.x · Cited by 173
Eng, C., Crossey, P. A., Mulligan, L. M., Healey, C. S., Houghton, C., Prowse, A., Chew, S. L., Dahia, P. L., O'Riordan, J. L., & Toledo, S. P. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.12.934 · Cited by 172
Pheochromocytoma in multiple endocrine neoplasia type 2: European study
Modigliani, E., VASEN, H. M., RAUE, K., DRALLE, H., FRILLING, A., GHERI, R. G., BRANDI, M. L., LIMBERT, E., NIEDERLE, B., FORGAS, L., et al. (1995) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1995.tb01211.x · Cited by 172
Taschner, P. E. M., Jansen, J. C., Baysal, B. E., Bosch, A., Rosenberg, E. H., Bröcker‐Vriends, A. H. J. T., van der Mey, A. G. L., van Ommen, G. B., Cornelisse, C. J., & Devilee, P. (2001) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.1144 · Cited by 165
Crossey, P. A., Foster, K., Richards, F. M., Phipps, M. E., Latif, F., Tory, K., Jones, M. H., Bentley, E., Kumar, R., Lerman, M., et al. (1994) · Human Genetics · doi:10.1007/bf00218913 · Cited by 148
Jenne, D. E., Tinschert, S., Reimann, H., Lasinger, W., Thiel, G., Hameister, H., & Kehrer‐Sawatzki, H. (2001) · The American Journal of Human Genetics · doi:10.1086/323043 · Cited by 146
Eng, C., Brody, L. C., Wagner, T. M. U., Devilee, P., Vijg, J., Szabo, C., Tavtigian, S. V., Nathanson, K. L., Ostrander, E., & Frank, T. S. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.12.824 · Cited by 142
Self-citationPheochromocytoma — Death of an Axiom
Dluhy, R. G. (2002) · New England Journal of Medicine · doi:10.1056/nejm200205093461911 · Cited by 129
Molecular Genetics of Succinate:Quinone Oxidoreductase in Eukaryotes
Scheffler, I. E. (1998) · Progress in nucleic acid research and molecular biology · doi:10.1016/s0079-6603(08)60895-8 · Cited by 125
Genetic predisposition to phaeochromocytoma: analysis of candidate genes GDNF, RET and VHL
Woodward, E. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.7.1051 · Cited by 124 · cited 1×
“The genetic etiology of these syndromes has been well defined; however, they account for only approximately half of all familial pheochromocytoma cases ( 10 ).”
BackgroundDifferences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma
Pomares, F. J., Canas, R., Rodriguez, J. M., Hernandez, A. M., Parrilla, P., & Tebar, F. J. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.3751208.x · Cited by 124
The neurofibromatoses: when less is more
Gutmann, D. H. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.747 · Cited by 121 · cited 2×
“Although NF1 acts as a tumor suppressor gene and both alleles are lost in a variety of NF1-associated malignancies, haploinsufficiency of NF1 alone may be sufficient to confer an increased tumor risk ( 19 ).”
BackgroundGomyo, Y., Ikeda, M., Osaki, M., Tatebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N., & Ito, H. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m · Cited by 121
Multiple endocrine neoplasia type 2B (mucosal neuroma syndrome, Wagenmann-Froboese syndrome).
Morrison, P. J., & Nevin, N. C. (1996) · Journal of Medical Genetics · doi:10.1136/jmg.33.9.779 · Cited by 108
Wagner, T. M. U., Möslinger, R., Muhr, D., Langbauer, G., Hirtenlehner, K., Concin, H., Doeller, W., Haid, A., Lang, A. H., Mayer, P., et al. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980729)77:3<354::aid-ijc8>3.0.co;2-n · Cited by 108
Fine mapping of an imprinted gene for familial nonchromaffin paragangliomas, on chromosome 11q23.
Baysal, B. E., Farr, J. E., Rubinstein, W. S., Galus, R. A., Johnson, K. A., Aston, C. E., Myers, E. N., Johnson, J. T., Carrau, R. L., Kirkpatrick, S. J., et al. (1997) · PubMed Central · Cited by 106
The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome.
Ponder, B. A. (1999) · PubMed · Cited by 104
Pheochromocytoma: Inherited associations, bilaterality, and cortex preservation
Inabnet, W. B., Caragliano, P., & Pertsemlidis, D. (2000) · Surgery · doi:10.1067/msy.2000.110846 · Cited by 97
Phaeochromocytoma in multiple endocrine neoplasia type 2 A: survey of 100 cases
Casanova, S., Rosenberg‐Bourgin, M., Farkast, D., Calmettes, C., Feingold, N., Heshmatl, H. M., Cohen, R., Conte‐Devolx, B., Guillausseau, P. J., Houdent, C., et al. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb00350.x · Cited by 97
Neurofibromatosis: Phenotype, Natural History, and Pathogenesis, 2nd Ed.
Cohen, B. H. (1992) · Neurology · doi:10.1212/wnl.42.12.2308-c · Cited by 89
Pheochromocytoma in multiple endocrine neoplasia type 2: a prospective study
Nguyễn, L., Niccoli, P., Caron, P. J., Bastié, D., Maes, B., Chabrier, G., Chabre, O., Rohmer, V., Lecomte, P., Henry, J. F., et al. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1440037 · Cited by 88 · cited 1×
“In the one prospective series ( 42 ) of pheochromocytoma in MEN 2A patients, the age of diagnosis was even lower than in the retrospective series (mean of 23.2 years); however, a smaller proportion of patients were diagnosed with pheochromocytomas than in other series, and only a small number of patients were followed…”
ResultInfluentialGermline mutations in thevhl gene in patients presenting with phaeochromocytomas
van der Harst, E., de Krijger, R. R., Dinjens, W. N. M., Weeks, L. E., Bonjer, H. J., Bruining, H. A., Lamberts, S. W. J., & Koper, J. W. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980729)77:3<337::aid-ijc5>3.0.co;2-p · Cited by 87
Tumorigenesis in neurofibromatosis: new insights and potential therapies
Reed, N. W., & Gutmann, D. H. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)01955-4 · Cited by 86
Detailed mapping of germline deletions of the von Hippel—Lindau disease tumour suppressor gene
Richards, F. M., Crossey, P. A., Phipps, M. E., Foster, K., Latif, F., Evans, D. G., Sampson, J. R., Lerman, M. I., Zbar, B., Affara, N. A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.4.595 · Cited by 85
Dannenberg, H., Dinjens, W. N. M., Abbou, M., van Urk, H., Pauw, B. K. H., Mouwen, D., Mooi, W. J., & de Krijger, R. R. (2002) · PubMed · Cited by 81
Milunsky, J. M., Maher, T. A., Michels, V. V., & Milunsky, A. (2001) · American Journal of Medical Genetics · doi:10.1002/ajmg.1270 · Cited by 77
Brauch, H., Hoeppner, W., Jähnig, H., Wöhl, T., Engelhardt, D., Spelsberg, F., & Ritter, M. M. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.12.4454 · Cited by 74
Badenhop, R. F., Cherian, S., Lord, R. S. A., Baysal, B. E., Taschner, P. E. M., & Schofield, P. R. (2001) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.1142 · Cited by 74
Decker, R., Peacock, M. L., Borst, M. J., SWEET, J., & THOMPSON, N. (1995) · Surgery · doi:10.1016/s0039-6060(05)80332-0 · Cited by 73
Beldjord, C., Desclaux-Arramond, F., Raffin‐Sanson, M., Corvol, J., de Keyzer, Y., LUTON, J. P., Plouin, P., & BERTAGNA, X. Y. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.7.7608256 · Cited by 71
Familial pheochromocytoma and islet cell tumor of the pancreas
Carney, J. A., Go, V. L. W., Gordon, H., Northcutt, R. C., Pearse, A. G. E., & Sheps, S. G. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90295-8 · Cited by 66
Identification of novel SDHD mutations in patients with phaeochromocytoma and/or paraganglioma
Cascón, A., Ruiz‐Llorente, S., Cebrián, A., Tellería, D., Rivero, J. C., Díez, J. J., Lopez-Ibarra, P. J., Jaunsolo, M. A., Benitez, J. J., & Robledo, M. (2002) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200829 · Cited by 62
Richards, F. M., Phipps, M. E., Latlf, F., Yao, M., Crossey, P. A., Foster, K., Llnehan, W. M., Affara, N. A., Lerman, M. I., Zbar, B., et al. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.879 · Cited by 62
Mutations in the RET protooncogene in sporadic pheochromocytomas
Lindor, N. M., Honchel, R., Khosla, S., & Thibodeau, S. N. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.2.7852530 · Cited by 61
Bar, M., Friedman, E., Jakobovitz, O., Leibowitz, G., Lerer, I., Abeliovich, D., & Gross, D. J. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.3251150.x · Cited by 60
Devilee, P., Van Schothorst, E. M., Bardoel, A. F. J., Bonsing, B., Kulpers‐Dijkshoorn, N., James, M. R., Fleuren, G., Van Mey, A. G. L. D., & Cornelisse, C. J. (1994) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.2870110202 · Cited by 59
Medullary thyroid carcinoma: role of genetic testing and calcitonin measurement
Lips, C. J. M., Höppener, J. W. M., & Thijssen, J. H. H. (2001) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/0004563011900614 · Cited by 56
Familial Multiple Glomus Tumors and Pheochromocytomas
Parkin, J. L. (1981) · Annals of Otology Rhinology & Laryngology · doi:10.1177/000348948109000115 · Cited by 54
Brauch, H. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.12.4101 · Cited by 51
Patterns of associations of clinical features in neurofibromatosis 1 (NF1)
Szudek, J., Evans, D. G., & Friedman, J. M. (2002) · Human Genetics · doi:10.1007/s00439-002-0871-7 · Cited by 51
Aguiar, R. C. T., Cox, G., Pomeroy, S. L., & Dahia, P. L. M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.6.7547 · Cited by 50 · cited 3×
“The mutation identified in SDHD was identical to that found in an unrelated paraganglioma family ( 84 ).”
BackgroundResultInfluentialMolecular pathology of von Hippel–Lindau disease and the VHL tumour suppressor gene
Richards, F. M. (2001) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399401002654 · Cited by 49
Frank‐Raue, K., Kratt, T., Höppner, W., Buhr, H. J., Ziegler, R., & Raue, F. (1996) · European Journal of Endocrinology · doi:10.1530/eje.0.1350222 · Cited by 43
Aguiar, R. C. T. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.6.2890 · Cited by 38
Januszewicz, A., Neumann, H. P. H., Łoń, I., Szmigielski, C. A., Symonides, B., Kabat, M., Apel, T. W., Wocial, B., Łapiński, M., & Januszewicź, W. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018080-00005 · Cited by 18
Case 13-2001: Genetic Testing in Pheochromocytoma
Neumann, H. P., Reincke, M., & Eng, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108163450715 · Cited by 4
Familial Pheochromocytoma: A Report of 2 Cases in a Kindred
Kaufman, J. J., & Franklin, S. S. (1979) · The Journal of Urology · doi:10.1016/s0022-5347(17)56999-2 · Cited by 4
Research works printed but not linked: 8
- Baysal, 1997, American journal of human genetics, 60, 121
- 1997, 79, 2125, 10.1002/(sici)1097-0142(19970601)79:11<2125::aid-cncr9>3.0.co;2-n · doi:10.1002/(sici)1097-0142(19970601)79:11<2125::aid-cncr9>3.0.co;2-n · Paper page
- Ponder, 1999, Cancer Research, 59, 1736s
- Prowse, 1997, American journal of human genetics, 60, 765
- Eisenhofer, 2001, Journal of Clinical Endocrinology & Metabolism, 86, 1999, 10.1210/jc.86.5.1999 · doi:10.1210/jc.86.5.1999 · Paper page
- Gimm, 2000, Cancer Research, 60, 6822
- Lindor, 1995, Journal of Clinical Endocrinology & Metabolism, 80, 627, 10.1210/jc.80.2.627 · doi:10.1210/jc.80.2.627
- Beldjord, 1995, Journal of Clinical Endocrinology & Metabolism, 80, 2063, 10.1210/jc.80.7.2063 · doi:10.1210/jc.80.7.2063
Cited by
Lenders, J. W., Eisenhofer, G., Mannelli, M., & Pacak, K. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67139-5 · Cited by 1,524
Pheochromocytoma and Paraganglioma
Neumann, H. P. H., Young, W. F., & Eng, C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1806651 · Cited by 736
Hereditary Cancer Predisposition Syndromes
Garber, J. E., & Offit, K. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.042 · Cited by 697
Genetic Testing in Pheochromocytoma or Functional Paraganglioma
Amar, L., Bertherat, J., Baudin, E., Ajzenberg, C., Bressac-de Paillerets, B., Chabre, O., Chamontin, B., Delemer, B., Giraud, S., Murat, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.1484 · Cited by 684
Pheochromocytoma: recommendations for clinical practice from the First International Symposium
Pacak, K., Eisenhofer, G., Ahlman, H., Bornstein, S. R., Gimenez-Roqueplo, A.-P., Grossman, A. B., Kimura, N., Mannelli, M., McNicol, A. M., & Tischler, A. S. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0396 · Cited by 680
Metadata
- Authors
- Bryant, J., Farmer, J., Kessler, L. J., Townsend, R. R., & Nathanson, K. L.
- Affiliations
- University of Pennsylvania (US)
- Corresponding author
- Bryant, J.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-19
- Volume
- 95
- Issue
- 16
- Pages
- 1196-1204
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2147035069
- Cited by
- 250
- References
- 102
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 8 · 2016: 5 · 2015: 12 · 2014: 10 · 2013: 13 · 2012: 11
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (K08CA084030, K08 CA84030)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Clinical Neurology › Neurofibromatosis and Schwannoma Cases
- Health Sciences › Medicine › Oncology › Ear and Head Tumors
- Keywords
- pheochromocytoma, paraganglioma, familial pheochromocytoma, germline mutations, RET, VHL, SDHB, SDHD, succinate dehydrogenase, neurofibromatosis type 1, multiple endocrine neoplasia type 2, von Hippel-Lindau disease, genetic counseling, genetic evaluation, hereditary cancer
- MeSH terms
- Adrenal Gland Neoplasms, Diagnosis, Differential, Genetic Markers, von Hippel-Lindau Disease, Humans, Neurofibromatosis 1, Paraganglioma, Extra-Adrenal, Paraneoplastic Syndromes, Pheochromocytoma, Succinate Dehydrogenase, Biomarkers, Tumor, Germ-Line Mutation, Multiple Endocrine Neoplasia Type 2a
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.